{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:41:21Z","timestamp":1780486881780,"version":"3.54.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,22]],"date-time":"2014-06-22T00:00:00Z","timestamp":1403395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11904-014-0212-1","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T02:16:56Z","timestamp":1403317016000},"page":"212-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Drug Interactions and Antiretroviral Drug Monitoring"],"prefix":"10.1007","volume":"11","author":[{"given":"Matthew","family":"Foy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. John","family":"Sperati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,22]]},"reference":[{"key":"212_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","volume":"43","author":"FJ Palella Jr","year":"2006","unstructured":"Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27\u201334.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cger.2007.02.004","volume":"23","author":"VP Luther","year":"2007","unstructured":"Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med. 2007;23:567\u201383. vii.","journal-title":"Clin Geriatr Med"},{"key":"212_CR3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1086\/523577","volume":"45","author":"JL Goulet","year":"2007","unstructured":"Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593\u2013601.","journal-title":"Clin Infect Dis"},{"key":"212_CR4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1540","volume":"15","author":"C Marzolini","year":"2010","unstructured":"Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15:413\u201323.","journal-title":"Antivir Ther"},{"key":"212_CR5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/j.1552-4604.1998.tb04398.x","volume":"38","author":"LL Moltke von","year":"1998","unstructured":"von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998;38:106\u201311.","journal-title":"J Clin Pharmacol"},{"key":"212_CR6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2011.06.007","volume":"132","author":"G Minuesa","year":"2011","unstructured":"Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011;132:268\u201379.","journal-title":"Pharmacol Ther"},{"key":"212_CR7","first-page":"136","volume":"11","author":"RB Kim","year":"2003","unstructured":"Kim RB. Drug transporters in HIV Therapy. Top HIV Med. 2003;11:136\u20139.","journal-title":"Top HIV Med"},{"key":"212_CR8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.109.027706","volume":"37","author":"AS Belanger","year":"2009","unstructured":"Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37:1793\u20136.","journal-title":"Drug Metab Dispos"},{"key":"212_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00228-006-0241-9","volume":"63","author":"Y Mano","year":"2007","unstructured":"Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol. 2007;63:211\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"212_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2011.558839","volume":"7","author":"I Jimenez-Nacher","year":"2011","unstructured":"Jimenez-Nacher I, Alvarez E, Morello J, Rodriguez-Novoa S, de Andres S, Soriano V. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457\u201377. This paper comprehensively reviews potential DDIs among antiretroviral medications and other drugs and describes potential mechanisms for these DDIs.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"212_CR11","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf . Accessed 5 Apr 2014. This panel report provides comprehensive guidelines for the antiretroviral treatment of HIV-infected patients, which are updated regularly by a panel of experts.It includes helpful tables for various DDIs."},{"key":"212_CR12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/jac\/dkn252","volume":"62","author":"I Jimenez-Nacher","year":"2008","unstructured":"Jimenez-Nacher I, Garcia B, Barreiro P, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. 2008;62:816\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"212_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAD.0000000000000033","volume":"28","author":"SM Baxi","year":"2014","unstructured":"Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions\u2014age, low BMI, ritonavir use, mild renal impairment\u2014affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS. 2014;28:59\u201366.","journal-title":"AIDS"},{"key":"212_CR14","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.01064-08","volume":"53","author":"A Pruvost","year":"2009","unstructured":"Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"212_CR15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","volume":"43","author":"BP Kearney","year":"2006","unstructured":"Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278\u201383.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2009.142","volume":"5","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563\u201373.","journal-title":"Nat Rev Nephrol"},{"key":"212_CR17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","volume":"12","author":"T Cihlar","year":"2007","unstructured":"Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267\u201372.","journal-title":"Antivir Ther"},{"key":"212_CR18","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.00671-07","volume":"51","author":"L Tong","year":"2007","unstructured":"Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51:3498\u2013504.","journal-title":"Antimicrob Agents Chemother"},{"key":"212_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","volume":"16","author":"V Soriano","year":"2011","unstructured":"Soriano V, Arasteh K, Migrone H, et al. Nevirapine vs atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339\u201348.","journal-title":"Antivir Ther"},{"key":"212_CR20","doi-asserted-by":"crossref","first-page":"e1001236","DOI":"10.1371\/journal.pmed.1001236","volume":"9","author":"S Lockman","year":"2012","unstructured":"Lockman S, Hughes M, Sawe F, et al. Nevirapine- vs lopinavir\/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012;9:e1001236.","journal-title":"PLoS Med"},{"key":"212_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","volume":"34","author":"KE Sherman","year":"2002","unstructured":"Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831\u20137.","journal-title":"Clin Infect Dis"},{"key":"212_CR22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e3283471cce","volume":"25","author":"JJ Helm van der","year":"2011","unstructured":"van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25:1083\u201391.","journal-title":"AIDS"},{"key":"212_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","volume":"44","author":"N Brau","year":"2006","unstructured":"Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47\u201355.","journal-title":"J Hepatol"},{"key":"212_CR24","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","volume":"22","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979\u201391.","journal-title":"AIDS"},{"key":"212_CR25","doi-asserted-by":"crossref","unstructured":"Pawlotsky JM. New Hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176\u201392. This review describes the new antiviral agents for the treatment of HCV, including those which are already FDA-approved and those which are still in development.","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"212_CR26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3851\/IMP2356","volume":"17","author":"V Garg","year":"2012","unstructured":"Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17:1211\u201321.","journal-title":"Antivir Ther"},{"key":"212_CR27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/cid\/cis968","volume":"56","author":"EG Hulskotte","year":"2013","unstructured":"Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718\u201326. This paper showed the important interactions between the novel anti-HCV agent, boceprevir, and several RTV-boosted PIs.","journal-title":"Clin Infect Dis"},{"key":"212_CR28","unstructured":"Vertex Pharmaceuticals: Incivek (telaprevir) prescribing information [online]. Available at: http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf . Accessed 16 Apr 2014."},{"key":"212_CR29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cid\/cit693","volume":"58","author":"A Gutierrez-Valencia","year":"2014","unstructured":"Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, et al. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clin Infect Dis. 2014;58:268\u201373. This paper provided evidence that supports the important role of RTV in the observed interactions between telaprevir and RTV-boosted atazanavir and likely other RTV-boosted PIs.","journal-title":"Clin Infect Dis"},{"key":"212_CR30","unstructured":"Janssen: Olysio (simeprevir) capsules. Available at: http:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf . Accessed 16 Apr 2014."},{"key":"212_CR31","unstructured":"Merck: Victrelis (boceprevir) capsules prescribing information. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf . Accessed 16 Apr 2014."},{"key":"212_CR32","unstructured":"Gilead: Solvadi (sofosbuvir) tablets. Prescribing information. Available at: http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/sovaldi\/sovaldi_pi.pdf . Accessed 16 Apr 2014."},{"key":"212_CR33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","volume":"18","author":"M Bifano","year":"2013","unstructured":"Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931\u201340.","journal-title":"Antivir Ther"},{"key":"212_CR34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.aids.0000171410.76607.f8","volume":"19","author":"EC Seaberg","year":"2005","unstructured":"Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953\u201360.","journal-title":"AIDS"},{"key":"212_CR35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1545109711418361","volume":"11","author":"S Medina-Torne","year":"2012","unstructured":"Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Phys AIDS Care. 2012;11:20\u20135.","journal-title":"J Int Assoc Phys AIDS Care"},{"key":"212_CR36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1097\/HJH.0b013e32830ef5fb","volume":"26","author":"M Baekken","year":"2008","unstructured":"Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126\u201333.","journal-title":"J Hypertens"},{"key":"212_CR37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10096-003-1034-z","volume":"22","author":"BM Bergersen","year":"2003","unstructured":"Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22:731\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"212_CR38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1345\/aph.1Q546","volume":"46","author":"H Peyriere","year":"2012","unstructured":"Peyriere H, Eiden C, Macia JC, Reynes J. Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother. 2012;46:703\u20139.","journal-title":"Ann Pharmacother"},{"key":"212_CR39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1524-6175.2006.04482.x","volume":"7","author":"DA Sica","year":"2005","unstructured":"Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens. 2005;7:21\u20136.","journal-title":"J Clin Hypertens"},{"key":"212_CR40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2007.02.014","volume":"381","author":"G Siest","year":"2007","unstructured":"Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta. 2007;381:26\u201331.","journal-title":"Clin Chim Acta"},{"key":"212_CR41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1345\/aph.1L497","volume":"43","author":"MD Liedtke","year":"2009","unstructured":"Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother. 2009;43:322\u20138.","journal-title":"Ann Pharmacother"},{"key":"212_CR42","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1089\/apc.2012.0068","volume":"26","author":"AM Anderson","year":"2012","unstructured":"Anderson AM, Chane T, Patel M, Chen S, Xue W, Easley KA. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. AIDS Patient Care STDS. 2012;26:454\u201362.","journal-title":"AIDS Patient Care STDS"},{"key":"212_CR43","doi-asserted-by":"crossref","unstructured":"Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48:734-40.","DOI":"10.1177\/1060028014523115"},{"key":"212_CR44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","volume":"76","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"212_CR45","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1124\/dmd.109.028498","volume":"37","author":"K Hagihara","year":"2009","unstructured":"Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145\u201352.","journal-title":"Drug Metab Dispos"},{"key":"212_CR46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-7843.2012.00932.x","volume":"112","author":"V Ancrenaz","year":"2013","unstructured":"Ancrenaz V, Deglon J, Samer C, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112:132\u20137.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"212_CR47","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","volume":"73","author":"N Ferri","year":"2013","unstructured":"Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681\u2013709.","journal-title":"Drugs"},{"key":"212_CR48","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1086\/367562","volume":"36","author":"M Dube","year":"2003","unstructured":"Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis. 2003;36:S79\u201383.","journal-title":"Clin Infect Dis"},{"key":"212_CR49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"212_CR50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"MP Dube","year":"2003","unstructured":"Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613\u201327.","journal-title":"Clin Infect Dis"},{"key":"212_CR51","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1177\/0091270011427907","volume":"52","author":"CL Aquilante","year":"2012","unstructured":"Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir\/ritonavir and pravastatin. J Clin Pharmacol. 2012;52:1725\u201338.","journal-title":"J Clin Pharmacol"},{"key":"212_CR52","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/0091270011407494","volume":"52","author":"D Samineni","year":"2012","unstructured":"Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir\/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52:922\u201331.","journal-title":"J Clin Pharmacol"},{"key":"212_CR53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAD.0b013e328331d2ab","volume":"24","author":"E Aslangul","year":"2010","unstructured":"Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin vs pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77\u201383.","journal-title":"AIDS"},{"key":"212_CR54","doi-asserted-by":"crossref","unstructured":"Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol. 2014;54:649\u201356.","DOI":"10.1002\/jcph.256"},{"key":"212_CR55","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229\u201336.","journal-title":"Drug Metab Dispos"},{"key":"212_CR56","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/QAI.0b013e318251addb","volume":"60","author":"RE Morgan","year":"2012","unstructured":"Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM. Effects of steady-state lopinavir\/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012;60:158\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR57","doi-asserted-by":"crossref","unstructured":"Sponseller CA. Pitavastatin 4 mg provides greater LDL-C reduction compared with pravastatin 40 mg over 12 weeks of treatment in HIV-infected adults with dyslipidemia. In: 20th Conference on Retroviruses & Opportunistic Infections: Atlanta, GA; 2013.","DOI":"10.1016\/j.jacl.2013.03.051"},{"key":"212_CR58","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa1001197","volume":"363","author":"PG Stock","year":"2010","unstructured":"Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004\u201314.","journal-title":"N Engl J Med"},{"key":"212_CR59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-6143.2007.02061.x","volume":"8","author":"ME Roland","year":"2008","unstructured":"Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355\u201365.","journal-title":"Am J Transplant"},{"key":"212_CR60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0956462413493266","volume":"25","author":"EN Gathogo","year":"2014","unstructured":"Gathogo EN, Hamzah L, Hilton R, et al. Kidney transplantation in HIV-positive adults: the UK experience. Int J STD Aids. 2014;25:57\u201366.","journal-title":"Int J STD Aids"},{"key":"212_CR61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","volume":"2","author":"J Schiff","year":"2007","unstructured":"Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374\u201384.","journal-title":"Clin J Am Soc Nephrol"},{"key":"212_CR62","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200746110-00002","volume":"46","author":"E Teicher","year":"2007","unstructured":"Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet. 2007;46:941\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"212_CR63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.TP.0000165111.09687.4E","volume":"80","author":"L Frassetto","year":"2005","unstructured":"Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation. 2005;80:13\u20137.","journal-title":"Transplantation"},{"key":"212_CR64","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/j.1600-6143.2007.02007.x","volume":"7","author":"LA Frassetto","year":"2007","unstructured":"Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816\u201320.","journal-title":"Am J Transplant"},{"key":"212_CR65","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1053\/jlts.2002.34921","volume":"8","author":"AK Jain","year":"2002","unstructured":"Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838\u201340.","journal-title":"Liver Transpl"},{"key":"212_CR66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429\u201355.","journal-title":"Clin Pharmacokinet"},{"key":"212_CR67","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00003088-200443120-00004","volume":"43","author":"SU Sankatsing","year":"2004","unstructured":"Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet. 2004;43:823\u201332.","journal-title":"Clin Pharmacokinet"},{"key":"212_CR68","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00126334-199908150-00002","volume":"21","author":"D Margolis","year":"1999","unstructured":"Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr. 1999;21:362\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00126334-200209010-00006","volume":"31","author":"DM Margolis","year":"2002","unstructured":"Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002;31:45\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR70","doi-asserted-by":"crossref","unstructured":"Trkulja V, Lalic Z, Nad-Skegro S, et al. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. Ther Drug Monit. 2014. doi: 10.1097\/FTD.0000000000000052 .","DOI":"10.1097\/FTD.0000000000000052"},{"key":"212_CR71","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","volume":"35","author":"K Kassahun","year":"2007","unstructured":"Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657\u201363.","journal-title":"Drug Metab Dispos"},{"key":"212_CR72","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1600-6143.2009.02684.x","volume":"9","author":"L Tricot","year":"2009","unstructured":"Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9:1946\u201352.","journal-title":"Am J Transplant"},{"key":"212_CR73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2009.11.004","volume":"85","author":"DJ McColl","year":"2010","unstructured":"McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antiviral Res. 2010;85:101\u201318.","journal-title":"Antiviral Res"},{"key":"212_CR74","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00636-10","volume":"54","author":"JJ Kiser","year":"2010","unstructured":"Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010;54:4999\u20135003.","journal-title":"Antimicrob Agents Chemother"},{"key":"212_CR75","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/jac\/dkr139","volume":"66","author":"P Patel","year":"2011","unstructured":"Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S\/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66:1567\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"212_CR76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/QAI.0b013e31829ecd3b","volume":"64","author":"S Ramanathan","year":"2013","unstructured":"Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64:45\u201350. This study demonstrated that boosted elvitegravirinteracts with antacids but notwith H 2 R-blockers or PPis. Its interaction with antacid is likely due to chelation of divalent ions.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"212_CR77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/apc.2011.0113","volume":"25","author":"X Wang","year":"2011","unstructured":"Wang X, Boffito M, Zhang J, et al. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS. 2011;25:509\u201315.","journal-title":"AIDS Patient Care STDS"},{"key":"212_CR78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/17425255.3.2.197","volume":"3","author":"SM McCabe","year":"2007","unstructured":"McCabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007;3:197\u2013207.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"212_CR79","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","volume":"50","author":"S Ramanathan","year":"2011","unstructured":"Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229\u201344.","journal-title":"Clin Pharmacokinet"},{"key":"212_CR80","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/596503","volume":"48","author":"M Iwamoto","year":"2009","unstructured":"Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48:489\u201392.","journal-title":"Clin Infect Dis"},{"key":"212_CR81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/COH.0b013e3282f82c06","volume":"3","author":"AK Pau","year":"2008","unstructured":"Pau AK. Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS. 2008;3:319\u201324.","journal-title":"Curr Opin HIV AIDS"},{"key":"212_CR82","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1086\/656237","volume":"51","author":"D Krakower","year":"2010","unstructured":"Krakower D, Kwan CK, Yassa DS, Colvin RA. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis. 2010;51:813\u201322. This article evaluates several online resources, which are clinically useful in the management of potential DDIs among HIV-infected patients.","journal-title":"Clin Infect Dis"},{"key":"212_CR83","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1086\/501464","volume":"42","author":"DW Haas","year":"2006","unstructured":"Haas DW. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis. 2006;42:1197\u20139.","journal-title":"Clin Infect Dis"},{"key":"212_CR84","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/501458","volume":"42","author":"RE Nettles","year":"2006","unstructured":"Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189\u201396.","journal-title":"Clin Infect Dis"},{"key":"212_CR85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FTD.0b013e3182791f8c","volume":"35","author":"JA Schoenenberger","year":"2013","unstructured":"Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit. 2013;35:71\u20137.","journal-title":"Ther Drug Monit"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-014-0212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-014-0212-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-014-0212-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T13:28:10Z","timestamp":1689341290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-014-0212-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,22]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s11904-014-0212-1","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,22]]}}}